Clinical bottom line
Portal hypertensive gastropathy (PHG) is a common mucosal abnormality in patients with portal hypertension that can cause chronic gastrointestinal bleeding and anemia. Recent advances emphasize endoscopic assessment combined with medical therapies targeting portal pressure reduction as the cornerstone of management. Non-selective beta-blockers remain first-line pharmacotherapy, while endoscopic interventions are reserved for refractory bleeding. Emerging endoscopic imaging techniques may improve diagnosis and risk stratification but require further validation. Overall, individualized treatment balancing bleeding risk and portal hypertension severity is essential.
What the evidence shows
PHG is characterized by a mosaic-like or “snake-skin” appearance of the gastric mucosa due to dilated submucosal vessels and mucosal edema in the setting of portal hypertension (Cubillas et al., 2010). It is estimated to affect up to 80% of patients with cirrhosis and portal hypertension, with bleeding occurring in a smaller subset (Garcia-Tsao et al., 2004). The pathophysiology involves increased portal venous pressure leading to mucosal congestion and fragility.
The primary therapeutic approach focuses on reducing portal pressure. Non-selective beta-blockers (NSBBs) such as propranolol or nadolol have demonstrated efficacy in decreasing the risk of bleeding by lowering portal venous inflow (Bresci et al., 2007). NSBBs remain the mainstay of medical management for PHG-related bleeding prevention. In cases of acute or refractory bleeding, endoscopic therapies such as argon plasma coagulation (APC) or band ligation have been employed, although evidence is limited and mostly extrapolated from variceal bleeding management (Soldner et al., 2024).
Recent endoscopic advances including high-definition imaging and narrow-band imaging have improved visualization of mucosal changes, potentially aiding in the differentiation of PHG from other gastric lesions and in bleeding risk stratification (Vanderschueren et al., 2023). However, these technologies are not yet standard practice and require further prospective validation.
Surgical or radiological interventions such as transjugular intrahepatic portosystemic shunt (TIPS) may be considered in patients with severe portal hypertension and refractory bleeding, but these carry significant risks and are reserved for select cases (Garcia-Tsao et al., 2004).
Caveats and uncertainty
Despite advances, the evidence base for PHG management remains limited by a lack of large randomized controlled trials specifically targeting this condition. Most recommendations are extrapolated from studies on portal hypertension and variceal bleeding. The natural history of PHG bleeding is variable, and predictors of bleeding risk are not well defined.
Endoscopic therapies for PHG bleeding are largely based on small case series or expert opinion, and their comparative effectiveness versus medical therapy alone is unclear. The role of novel endoscopic imaging techniques in routine clinical practice is still investigational.
Additionally, the impact of newer portal pressure–lowering agents or combination therapies on PHG outcomes has not been systematically studied. Patient heterogeneity, including liver disease severity and comorbidities, complicates treatment decisions.
How this may change practice
Clinicians should maintain a high index of suspicion for PHG in patients with portal hypertension presenting with chronic anemia or occult gastrointestinal bleeding. Endoscopic evaluation remains essential for diagnosis and exclusion of other causes.
Non-selective beta-blockers should be optimized as first-line therapy to reduce portal pressure and bleeding risk. Endoscopic treatment modalities may be considered for patients with active or refractory bleeding but require individualized assessment given limited evidence.
Emerging endoscopic imaging technologies may soon enhance diagnostic accuracy and risk stratification, potentially guiding more tailored interventions. Integration of these tools into clinical workflows will depend on further validation studies.
Multidisciplinary management involving hepatologists, gastroenterologists, and interventional radiologists is critical for complex cases, especially when considering TIPS or surgical options.